John Chirgwin - Publications

Affiliations: 
University of Virginia, Charlottesville, VA 
Area:
Biochemistry, Molecular Biology

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA. Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget. 8: 86447-86462. PMID 29156807 DOI: 10.18632/oncotarget.21200  0.32
2015 Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA. The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell. 27: 809-21. PMID 25982816 DOI: 10.1016/J.Ccell.2015.04.009  0.32
2014 Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Research : Bcr. 16: 458. PMID 25439669 DOI: 10.1186/S13058-014-0458-Y  0.32
2012 Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Research. 72: 6247-56. PMID 23002206 DOI: 10.1158/0008-5472.CAN-12-1444  0.32
2011 Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 2523-36. PMID 21698666 DOI: 10.1002/jbmr.450  0.32
2009 Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. Plos One. 4: e6896. PMID 19727403 DOI: 10.1371/Journal.Pone.0006896  0.32
2009 Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents targeting prostate cancer bone metastasis. Anti-Cancer Agents in Medicinal Chemistry. 9: 1079-88. PMID 19719455 DOI: 10.2174/187152009789735008  0.32
2009 Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology. 310: 71-81. PMID 19616059 DOI: 10.1016/J.Mce.2009.07.004  0.32
2008 Mohammad KS, Chirgwin JM, Guise TA. Assessing new bone formation in neonatal calvarial organ cultures. Methods in Molecular Biology (Clifton, N.J.). 455: 37-50. PMID 18463809 DOI: 10.1007/978-1-59745-104-8_3  0.32
2007 Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Molecular Cancer Therapeutics. 6: 2609-17. PMID 17938257 DOI: 10.1158/1535-7163.MCT-07-0234  0.32
2007 Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. Journal of Cellular Biochemistry. 102: 1333-42. PMID 17907152 DOI: 10.1002/jcb.21556  0.32
2007 Kingsley LA, Chirgwin JM, Guise TA. Breaking new ground to build bone. Proceedings of the National Academy of Sciences of the United States of America. 104: 10753-4. PMID 17581868 DOI: 10.1073/pnas.0704357104  0.32
2007 Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology (Baltimore, Md.). 21: 486-98. PMID 17068196 DOI: 10.1210/me.2006-0346  0.32
2007 Bartholin L, Wessner LL, Chirgwin JM, Guise TA. The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Letters. 246: 230-6. PMID 16616811 DOI: 10.1016/j.canlet.2006.02.019  0.32
2006 Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Reviews. 25: 621-33. PMID 17165131 DOI: 10.1007/S10555-006-9023-1  0.32
2006 Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6213s-6216s. PMID 17062703 DOI: 10.1158/1078-0432.Ccr-06-1007  0.32
2006 Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology. 18: 396-404. PMID 16763461 DOI: 10.1097/01.bor.0000231909.35043.da  0.32
2006 Chirgwin JM, Guise TA. Does prostate-specific antigen contribute to bone metastases? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1395-7. PMID 16533760 DOI: 10.1158/1078-0432.CCR-06-0005  0.32
2006 Zudaire E, Martínez A, Garayoa M, Pío R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. The American Journal of Pathology. 168: 280-91. PMID 16400030 DOI: 10.2353/ajpath.2006.050291  0.32
2005 Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Research. 65: 11001-9. PMID 16322249 DOI: 10.1158/0008-5472.Can-05-2630  0.32
2005 Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clinical Breast Cancer. 5: S46-53. PMID 15807924  0.32
2003 Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinical Orthopaedics and Related Research. S32-8. PMID 14600590 DOI: 10.1097/01.blo.0000093055.96273.69  0.32
2003 Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Seminars in Oncology. 30: 717-23. PMID 14571419  0.32
2003 Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America. 100: 10954-9. PMID 12941866 DOI: 10.1073/Pnas.1830978100  0.32
2002 Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. The Journal of Biological Chemistry. 277: 24571-8. PMID 11964407 DOI: 10.1074/jbc.M202561200  0.32
1999 Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation. 103: 197-206. PMID 9916131 DOI: 10.1172/Jci3523  0.32
Show low-probability matches.